At the news
? BEARISHIMPACT 6/10 8-K filed Jun 18, 2026 at 07:00 ET
NovoCure announced that its Phase 3 TRIDENT trial failed to meet the primary endpoint of overall survival for earlier initiation of TTFields therapy in newly diagnosed glioblastoma. The median OS was nearly identical (17.7 vs 17.5 months, p=0.519), making this a clear negative read for the company's lead product expansion strategy.
- Phase 3 TRIDENT trial did not demonstrate statistically significant improvement in overall survival for Early Start Arm vs Maintenance Start Arm (HR 0.953; p=0.519)
- Median overall survival: 17.7 months (Early Start) vs 17.5 months (Maintenance Start)
- One-, two-, and three-year survival rates were similar between arms (Early Start: 70.9%, 33.9%, 22.5%; Maintenance Start: 72.0%, 31.6%, 18.4%)
- Trial enrolled 981 patients; no new safety signals observed
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access